The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment

Sasidhar Gunturu[1]

In the past few years, researchers have been uncovering some fascinating connections between neuroscience and endocrinology, which could lead to exciting new treatments for psychiatric disorders. One of the most intriguing areas of exploration involves the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs). Initially known for their ability to help manage diabetes, these drugs are now showing promise as a fresh approach to treating mental health conditions.[1] While it is still early days, there is hope that GLP-1 RAs could offer relief for people struggling with conditions such as depression, anxiety, and even neurodegenerative diseases.[2]

Understanding GLP-1 Agonists

GLP-1 is an incretin hormone primarily known for its role in glucose homeostasis and satiety regulation. It is released from enteroendocrine cells in the gut in response to nutrient intake. It plays a crucial role in the incretin effect, enhancing insulin secretion in a glucose-dependent manner. GLP-1 RAs, commonly used in managing type 2 diabetes, mimic the action of endogenous GLP-1, leading to improved glycemic control.[3]

Beyond glycemic regulation, GLP-1 and its agonists exert pleiotropic effects on the central nervous system (CNS). The widespread distribution of GLP-1 receptors in the brain suggests their involvement in modulating neuronal function, synaptic plasticity, and neurotransmitter release. This neural influence has sparked interest in exploring the potential neuropsychiatric effects of GLP-1 RAs.[4]

GLP-1 Agonists in Psychiatric Disorders

Depression and anxiety disorders weigh heavily on a global scale, and traditional treatments frequently do not deliver the desired results in terms of effectiveness and tolerability. As researchers delve into alternative therapeutic approaches, they have noticed improvements in mood among diabetic individuals who use GLP-1 RAs. This observation has sparked investigations into the potential of GLP-1 RAs in managing these psychiatric conditions.

Preclinical studies have provided preliminary evidence of GLP-1 RAs' antidepressant and anxiolytic properties.[5] Animal models have demonstrated that GLP-1 receptor activation promotes neurogenesis, enhances synaptic plasticity, and modulates stress response pathways in mood disorders.[6] Furthermore, GLP-1 RAs have been shown to attenuate neuroinflammation and oxidative stress, processes implicated in the pathophysiology of depression and anxiety.[7]

Human trials have also yielded promising results, with several clinical studies reporting improvements in depressive symptoms following treatment with GLP-1 RAs.[8,9] Moreover, preliminary evidence suggests potential benefits in conditions such as bipolar disorder and schizophrenia, hinting at the broad spectrum of psychiatric disorders that could potentially benefit from GLP-1-based

[1]Dept. of Psychiatry, BronxCare Health System, Bronx, New York, USA.

HOW TO CITE THIS ARTICLE: Gunturu S. The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment. *Indian J Psychol Med.* 2024;46(3):193–195.

Address for correspondence: Sasidhar Gunturu, Dept. of Psychiatry, BronxCare Health System, Bronx, New York 10456, USA.
E-mail: Sashi.dr@gmail.com

Submitted: 27 Mar. 2024
Accepted: 27 Mar. 2024
Published Online: 12 Apr. 2024

ACCESS THIS ARTICLE ONLINE
Website: journals.sagepub.com/home/szj
DOI: 10.1177/02537176241246744

interventions[10] Recent discoveries and incidental findings primarily observed in diabetic patients treated with GLP-1 RAs present an intriguing avenue for exploration. While these developments are undoubtedly exciting, the definitive role or mechanism of action has not yet been firmly established; instead, they remain the subject of hypothesis and conjecture.

However, one area that is particularly promising and receiving significant attention is the role of GLP-1 RAs in neurodegenerative disorders.[11] GLP-1 mimetics exhibit neuroprotective effects by crossing the blood–brain barrier, reducing β-amyloid plaques, preventing synaptic loss, improving memory impairments, and decreasing oxidative stress and inflammation in the brain.[4] Preclinical research indicates that semaglutide exhibits potential in the treatment of Alzheimer's disease (AD) and Parkinson's disease (PD). The AD models demonstrate the restoration of cell viability, enhanced autophagy, and decreased apoptosis. Conversely, in PD models, semaglutide improves motor impairments, diminishes inflammation and lipid peroxidation, and enhances the protection of dopaminergic neurons.[12]

However, clinical trials investigating semaglutide's effects on AD and PD are limited, with ongoing phase 3 trials for AD and a pending phase 2 trial for PD in the USA.[13,14] GLP-1 RAs, including semaglutide, may mitigate AD and PD risk through various mechanisms, although current evidence on cognitive benefits is inconclusive, with mixed results from trials involving liraglutide and exenatide.[15] Additionally, meta-analyses suggest potential benefits of GLP-1 RAs, particularly exenatide, on motor symptoms in PD, with low-certainty evidence indicating improvements in cognition.[15]

While investigating the role of GLP-1 RAs in psychiatric disorders, a crucial aspect ripe for testing lies in their potential to prevent cardiometabolic complications among patients taking antipsychotics. Research suggests that GLP-1 RAs are effective in reducing antipsychotic-associated body weight gain, particularly in patients treated with medications such as clozapine and olanzapine.[16] Although an interesting first-ever clinical trial, the TAO study revealed a moderate weight loss of 2.3 kg over three months, irrespective of the treatment arm, accompanied by slight improvements in fasting plasma glucose, triglycerides, total cholesterol, and HDL cholesterol levels.[17] Exenatide showed a trend-level indication of lowering HbA1c in the study.[17] Exenatide and liraglutide have been extensively studied and have demonstrated promising outcomes in reducing cardiometabolic complications in patients undergoing antipsychotic treatment.[17] Therefore, the use of GLP-1 receptor agonists presents a promising strategy to mitigate the cardiometabolic complications associated with antipsychotic treatment.

Mechanisms of Action

The precise mechanisms underlying the psychiatric effects of GLP-1 agonists remain the subject of ongoing research. However, several pathways have been proposed to contribute to their therapeutic actions:

Neurogenesis and Synaptic Plasticity

GLP-1 receptor activation promotes the proliferation and survival of neural progenitor cells in the hippocampus, a brain region implicated in mood regulation. Additionally, GLP-1 signaling enhances synaptic plasticity, facilitating adaptive changes in neuronal connectivity that underlie learning and memory processes.[11]

Neurotransmitter Modulation

GLP-1 receptors are expressed in brain regions that regulate mood and emotion, including the prefrontal cortex, amygdala, and hypothalamus. Activation of these receptors modulates the release of neurotransmitters such as serotonin, dopamine, and glutamate, which play critical roles in mood regulation and stress response.[7]

Neuroinflammation and Oxidative Stress

Chronic inflammation and oxidative stress have been implicated in the pathophysiology of psychiatric disorders. GLP-1 RAs possess anti-inflammatory and antioxidant properties, attenuating neuroinflammatory processes and oxidative damage, potentially mitigating neurodegenerative changes associated with psychiatric illness.[4]

Clinical Implications and Future Directions

The growing body of evidence endorsing the potential of GLP-1 RAs in psychiatric disorders presents significant promise for transforming mental health treatment approaches. Nevertheless, several crucial questions and challenges require careful consideration:

Delineating Optimal Treatment Strategies

Although initial studies have shown promising outcomes, especially in diabetic individuals, additional research is necessary to determine the best dosing schedules, treatment durations, and patient groups most likely to benefit from GLP-1 agonist therapy. Long-term studies are also required to evaluate the lasting effects of treatment and any potential side effects over extended periods.

Addressing Heterogeneity of Psychiatric Disorders

Psychiatric disorders are characterized by substantial heterogeneity in symptomatology, underlying neurobiology, and treatment response. Future research should strive to identify biomarkers and clinical predictors that can inform personalized treatment approaches and improve therapeutic outcomes.

Exploring Combination Therapies

Given the nature of psychiatric disorders, investigating the potential synergistic effects of GLP-1 RAs with existing pharmacotherapies or psychotherapeutic interventions represents a promising avenue for enhancing treatment efficacy and addressing treatment-resistant cases.

Investigating Neuroprotective Effects

Beyond symptom management, the neuroprotective properties of GLP-1 RAs hold implications for slowing disease progression and preserving cognitive function in neurodegenerative disorders such as Alzheimer's and Parkinson's. Some promising trials are underway

exploring the neuroprotective potential of GLP-1 agonists in these conditions.

Conclusion

In conclusion, the burgeoning evidence supporting the neuropsychiatric effects of GLP-1 RAs heralds a new frontier in mental health treatment. By harnessing the neurobiological pathways modulated by GLP-1 signaling, these agents promise targeted interventions that may address the underlying pathophysiology of psychiatric disorders. However, further research is needed to fully elucidate their mechanisms of action, optimize treatment strategies, and translate preclinical findings into clinical practice. With continued investigation and innovation, GLP-1 agonists may emerge as invaluable tools in the armamentarium against psychiatric illness, offering renewed hope for individuals grappling with these debilitating conditions.

Declaration of Conflicting Interests

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Sasidhar Gunturu https://orcid.org/0000-0002-6867-2394

References

1. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. *Mol Metab* 2021; 46: 101102. DOI: 10.1016/j.molmet.2020.101102.
2. Mansur RB, Lee Y, Subramaniapillai M, et al. Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists? *Neuropharmacology* 2018; 136: 335–342. DOI: 10.1016/j.neuropharm.2018.01.048.
3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). *Mol Metab* 2019; 30: 72–130. DOI: 10.1016/j.molmet.2019.09.010.
4. Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. *Front Endocrinol (Lausanne)* 2021; 12: 721135. DOI: 10.3389/fendo.2021.721135.
5. Laurindo LF, Barbalho SM, Guiguer EL, et al. GLP-1a: going beyond traditional use. *Int J Mol Sci* 2022; 23. DOI: 10.3390/ijms23020739.
6. Anderberg RH, Richard JE, Hansson C, et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. *Psychoneuroendocrinology* 2016; 65: 54–66. DOI: 10.1016/j.psyneuen.2015.11.021.
7. Kim YK, Kim OY, and Song J. Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function. *Front Pharmacol* 2020; 11: 1270. DOI: 10.3389/fphar.2020.01270.
8. Detka J and Głombik K. Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. *Pharmacol Rep* 2021; 73: 1020–1032. DOI: 10.1007/s43440-021-00274-8.
9. Chen X, Zhao P, Wang W, et al. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. *Am J Geriatr Psychiatry* 2024; 32: 117–127. DOI: 10.1016/j.jagp.2023.08.010.
10. Çiçekli MN, Tiryaki ES, Altun A, et al. GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway. *J Recept Signal Transduct Res* 2022; 42: 486–494. DOI: 10.1080/10799893.2022.2032747.
11. Reich N and Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review. *Front Neurosci* 2022; 16: 970925. DOI: 10.3389/fnins.2022.970925.
12. Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. *Front Aging Neurosci* 2016; 8: 108. DOI: 10.3389/fnagi.2016.00108.
13. Nørgaard CH, Friedrich S, Hansen CT, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind, randomized controlled trials and nationwide disease and prescription registers. *Alzheimers Dement (N Y)* 2022; 8: e12268. DOI: 10.1002/trc2.12268.
14. ClinicalTrials.gov. A research study investigating semaglutide in people with early Alzheimer's disease (EVOKE Plus). 2024. https://classic.clinicaltrials.gov/ct2/show/NCT04777409 (accessed 4 April 2024).
15. Nowell J, Blunt E, Gupta D, et al. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease. *Ageing Res Rev* 2023; 89: 101979. DOI: 10.1016/j.arr.2023.101979.
16. Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardiometabolic risk factors: a systematic review and individual participant data meta-analysis. *Diabetes Obes Metab* 2019; 21: 293–302. DOI: 10.1111/dom.13522.
17. Ebdrup BH, Broberg BV, Ishøy PL, et al. Erratum: effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2018; 20: 1327–1328. DOI: 10.1111/dom.13204.